CN1226294C - 稠合的杂芳族葡萄糖激酶活化剂 - Google Patents

稠合的杂芳族葡萄糖激酶活化剂 Download PDF

Info

Publication number
CN1226294C
CN1226294C CNB018194494A CN01819449A CN1226294C CN 1226294 C CN1226294 C CN 1226294C CN B018194494 A CNB018194494 A CN B018194494A CN 01819449 A CN01819449 A CN 01819449A CN 1226294 C CN1226294 C CN 1226294C
Authority
CN
China
Prior art keywords
cyclopentyl
phenyl
propionic acid
acid amide
methane sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018194494A
Other languages
English (en)
Chinese (zh)
Other versions
CN1476438A (zh
Inventor
温迪·利·科比特
约瑟夫·塞缪尔·格林伯西
南希－艾伦·海因斯
罗伯特·弗朗西斯·凯斯特
佩奇·埃兰·马哈尼
拉马坎斯·萨拉布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1476438A publication Critical patent/CN1476438A/zh
Application granted granted Critical
Publication of CN1226294C publication Critical patent/CN1226294C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNB018194494A 2000-12-06 2001-11-28 稠合的杂芳族葡萄糖激酶活化剂 Expired - Fee Related CN1226294C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25163700P 2000-12-06 2000-12-06
US60/251,637 2000-12-06

Publications (2)

Publication Number Publication Date
CN1476438A CN1476438A (zh) 2004-02-18
CN1226294C true CN1226294C (zh) 2005-11-09

Family

ID=22952803

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018194494A Expired - Fee Related CN1226294C (zh) 2000-12-06 2001-11-28 稠合的杂芳族葡萄糖激酶活化剂

Country Status (21)

Country Link
US (3) US6545155B2 (US06448399-20020910-C00006.png)
EP (1) EP1341774B1 (US06448399-20020910-C00006.png)
JP (1) JP4109111B2 (US06448399-20020910-C00006.png)
KR (1) KR100545431B1 (US06448399-20020910-C00006.png)
CN (1) CN1226294C (US06448399-20020910-C00006.png)
AR (1) AR031627A1 (US06448399-20020910-C00006.png)
AT (1) ATE316965T1 (US06448399-20020910-C00006.png)
AU (2) AU2002221902B2 (US06448399-20020910-C00006.png)
BR (1) BR0115999A (US06448399-20020910-C00006.png)
CA (1) CA2429642C (US06448399-20020910-C00006.png)
DE (1) DE60117059T2 (US06448399-20020910-C00006.png)
DK (1) DK1341774T3 (US06448399-20020910-C00006.png)
ES (1) ES2256340T3 (US06448399-20020910-C00006.png)
GT (1) GT200100243A (US06448399-20020910-C00006.png)
MX (1) MXPA03005119A (US06448399-20020910-C00006.png)
PA (1) PA8534301A1 (US06448399-20020910-C00006.png)
PE (1) PE20020753A1 (US06448399-20020910-C00006.png)
PT (1) PT1341774E (US06448399-20020910-C00006.png)
UY (1) UY27055A1 (US06448399-20020910-C00006.png)
WO (1) WO2002046173A1 (US06448399-20020910-C00006.png)
ZA (1) ZA200303748B (US06448399-20020910-C00006.png)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
US6775812B2 (en) * 2002-07-17 2004-08-10 Hewlett-Packard Development Company, L.P. Layout design process and system for providing bypass capacitance and compliant density in an integrated circuit
WO2004050645A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
WO2004031179A1 (en) 2002-10-03 2004-04-15 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
DE602004012858T2 (de) * 2003-06-20 2009-05-14 F. Hoffmann-La Roche Ag 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
DK1723128T3 (da) 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
AU2005214137B2 (en) * 2004-02-18 2008-05-29 Astrazeneca Ab Compounds
KR20070007103A (ko) * 2004-02-18 2007-01-12 아스트라제네카 아베 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도
EP1737870A1 (en) * 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
JP4700684B2 (ja) * 2004-04-02 2011-06-15 ノバルティス アーゲー ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体
JP2007533722A (ja) * 2004-04-21 2007-11-22 プロシディオン・リミテッド トリ（シクロ）置換アミド化合物
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
WO2006040527A1 (en) 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR20070083939A (ko) 2004-11-02 2007-08-24 반유 세이야꾸 가부시끼가이샤 아릴옥시 치환된 벤즈이미다졸 유도체
DE102005012872A1 (de) * 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2008542247A (ja) * 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての２−フェニル置換イミダゾール［４，５ｂ］ピリジン／ピラジンおよびプリン誘導体
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
NZ575514A (en) * 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP2009500442A (ja) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
AU2006267338B2 (en) 2005-07-13 2012-08-16 Msd K.K. Heterocycle-substituted benzimidazole derivative
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
US20090005391A1 (en) * 2005-11-03 2009-01-01 Matthew Colin Thor Fyfe Tricyclo Substituted Amides
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
AT503354B1 (de) * 2006-02-22 2008-07-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
EP2046755A2 (en) 2006-07-24 2009-04-15 F. Hoffmann-Roche AG Pyrazoles as glucokinase activators
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
WO2008079787A2 (en) * 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
BRPI0721143A2 (pt) * 2006-12-21 2014-03-11 Astrazeneca Ab Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
BRPI0808267A2 (pt) 2007-03-07 2014-07-22 Kyorin Phamaceutical Co., Ltd "composto representado pela formula geral (1) ou um sal farmeceuticamente aceitável do mesmo; método para o tratamento ou prevenção de diabetes ; uso do composto; composição farmacêutica e composto representado pela formula geral (3)".
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
TW200942239A (en) 2008-01-18 2009-10-16 Astellas Pharma Inc Phenylacetamide derivatives
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
WO2010021882A2 (en) 2008-08-19 2010-02-25 Janssen Pharmaceutica Nv Cold menthol receptor antagonists
EP2344458A1 (en) 2008-09-11 2011-07-20 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
EA018894B1 (ru) 2009-03-11 2013-11-29 Пфайзер Инк. N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
AR076221A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
EP3936608A1 (en) 2010-03-31 2022-01-12 The Scripps Research Institute Reprogramming cells
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
ES2489297B1 (es) 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
JP6769963B2 (ja) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
EP3294713B1 (en) 2015-05-15 2021-02-17 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ror gamma modulators
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
MX2020008905A (es) 2018-06-12 2020-12-03 Vtv Therapeutics Llc Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840550A (en) * 1971-05-24 1974-10-08 Ciba Geigy Corp Certain 6-isothiocyanobenzothiazoles
DK1169312T3 (da) * 1999-03-29 2005-01-31 Hoffmann La Roche Glucokinaseaktivatorer
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators

Also Published As

Publication number Publication date
US20020103241A1 (en) 2002-08-01
DK1341774T3 (da) 2006-06-12
DE60117059D1 (de) 2006-04-13
BR0115999A (pt) 2003-09-30
ATE316965T1 (de) 2006-02-15
US20020103199A1 (en) 2002-08-01
CA2429642A1 (en) 2002-06-13
ZA200303748B (en) 2004-08-16
ES2256340T3 (es) 2006-07-16
DE60117059T2 (de) 2006-10-26
AR031627A1 (es) 2003-09-24
JP4109111B2 (ja) 2008-07-02
MXPA03005119A (es) 2004-10-15
CN1476438A (zh) 2004-02-18
AU2190202A (en) 2002-06-18
US6448399B1 (en) 2002-09-10
JP2004517087A (ja) 2004-06-10
EP1341774B1 (en) 2006-02-01
CA2429642C (en) 2007-11-20
KR20030068555A (ko) 2003-08-21
US6441184B1 (en) 2002-08-27
US6545155B2 (en) 2003-04-08
PE20020753A1 (es) 2002-08-27
PT1341774E (pt) 2006-05-31
KR100545431B1 (ko) 2006-01-24
US20020107396A1 (en) 2002-08-08
EP1341774A1 (en) 2003-09-10
WO2002046173A1 (en) 2002-06-13
GT200100243A (es) 2002-06-04
UY27055A1 (es) 2002-07-31
AU2002221902B2 (en) 2006-11-23
PA8534301A1 (es) 2002-08-26

Similar Documents

Publication Publication Date Title
CN1226294C (zh) 稠合的杂芳族葡萄糖激酶活化剂
CN1209362C (zh) 四唑基－苯基乙酰胺的葡糖激酶激活剂
CN1247574C (zh) 异吲哚啉－1－酮葡糖激酶激活剂
CN1184214C (zh) α－酰基和α－杂原子取代的苯乙酰胺葡糖激酶活化剂
CN1151140C (zh) 葡糖激酶活化剂
CN1185219C (zh) 反式烯属葡糖激酶活化剂
CN1114402C (zh) 异噻唑酮类化合物、含它们的制剂及其用途
CN1043348C (zh) 不对称取代的黄嘌呤、其制备方法及其作为药物组合物的应用
CN1185220C (zh) 对－胺基取代的苯基酰胺葡糖激酶激活剂
CN1245394C (zh) 作为葡糖激酶激活剂的取代的苯乙酰胺及其用途
CN1131210C (zh) 杂环类酰胺化合物及其医药用途
CN1209361C (zh) 含乙内酰脲的葡糖激酶激活剂
CN1688574A (zh) 作为葡糖激酶(gk)激活剂的吲哚－3－甲酰胺
CN1050018A (zh) 苯甲酰基胍、它们的制备方法、它们作为药剂的应用以及含有它们的药剂
CN1294577A (zh) 钾通道抑制剂
CN1649859A (zh) 取代的苯基乙酰胺类及其作为葡糖激酶激活剂的应用
CN1638768A (zh) 调节ppar活性的噻唑和噁唑衍生物
CN1368961A (zh) 调节PPARγ活性的化合物
CN1659156A (zh) 新的胍基苯甲酰胺
CN1143319A (zh) 治疗心血管疾病，炎症和免疫病症的化合物及方法
CN1871244A (zh) 作为腺苷受体配体的噻唑并吡啶衍生物
CN1812972A (zh) 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
CN1604897A (zh) 作为腺苷受体配体的7－氨基苯并噻唑衍生物
CN1038640A (zh) 二环碳酰胺、其制备方法及含该物质的药物组合物
CN101080389A (zh) 具有抗增殖活性的茚满酰胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051109

Termination date: 20111128